Handelsavisen
prelaunch
Companies Healthcare OWLT.K
OW
OWLT.K NYSE Advanced Medical Equipment & Technology

Owlet Inc

$5,40
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
156,6M USD
P/E
EV / Rev
2,8x
Div yield
Op margin
-10,8 %
ROE
5,5 %
Net margin
-5,5 %
Debt / equity
-0,57
Beta
52w range
Volume
4,0k
Day range
$5,44–$6,07
Prev close
$5,73
Open
$5,71
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Owlet Inc is a provider of advanced medical equipment and technology, specializing in wearable health monitoring devices for infants and children.

Business. Owlet Inc (OWLT.K) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm is headquartered in the United States and is primarily listed on the New York Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %
SectorHealth Care
Industry groupAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
BUY5 analysts
5 buy0 hold0 sell
Avg 12m price target14,25

Analyst recommendations

5 analysts · consensus Buy
Buy5
Hold0
Sell0
12-month price target
14,25
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
5 analysts · indicative
Ownership
AMERIPRISE FINANCIAL INC
largest disclosed fund holder
Profitability
5,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning OWLT.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to OWLT.K. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Owlet Inc (OWLT.K) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm is headquartered in the United States and is primarily listed on the New York Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification99 %
    SectorHealth Care
    Industry groupAdvanced Medical Equipment & Technology
    AI synthesis
    GENERATED

    Owlet Inc operates with a negative equity position of -$20.83 million and a total debt of $11.85 million, indicating a leveraged capital structure. The company's liquidity position is constrained, with $15.36 million in cash and equivalents, but a current ratio of 1.01 suggests limited short-term liquidity buffer. The negative return on equity of 5.51% and a negative return on assets of -2.5% highlight the company's underperformance in generating returns from its equity and asset base.

    The company's operating income of -$2.24 million and net income of -$1.15 million indicate ongoing operational losses. These figures are below the industry median for profitability metrics, suggesting that Owlet Inc is not performing as well as its peers in terms of generating profit. The gross profit margin of 49.5% is relatively high, but this is offset by significant operating expenses that erode profitability.

    Owlet Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to market-specific risks and limits its ability to offset losses in one area with gains in another. The company's revenue of $20.70 million is modest compared to industry leaders, and there is no indication of significant geographic expansion.

    The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year. The negative operating cash flow of -$6.72 million and free cash flow of -$2.60 million indicate that the company is not generating sufficient cash to fund operations or growth initiatives. The capital expenditure of -$74,000 suggests minimal investment in long-term assets, which may limit future growth potential.

    The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative equity and high debt-to-equity ratio of -0.57 suggest potential financial instability. The dilution potential is low, but the company's negative net income and operating cash flow could necessitate future equity raises, which may dilute existing shareholders.

    Recent events include analyst estimates indicating a strong buy recommendation with a mean price target of $14.25 and a median price target of $14.50. These estimates suggest that analysts have a positive outlook on the company's future performance, despite its current financial challenges.

    Key takeaways
    • Owlet Inc is operating at a loss with negative equity and high debt, indicating financial distress.
    • The company's profitability metrics are below industry medians, suggesting underperformance relative to peers.
    • Owlet Inc's revenue is concentrated in a single segment with no geographic diversification, increasing business risk.
    • Analysts have a positive outlook on the company, with a mean price target significantly higher than the current market price.
    • The company's liquidity position is weak, with limited cash reserves and a current ratio near 1.0.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-05-07
    Q1 2026 · Quarter highlights
    Open report →

    Revenue $22.5M; Net margin -14.9%.

    Revenue$22.5M
    Operating income
    Net income-$3.3M
    Free cash flow
    EPS
    Operating cash flow-$5.0M
    Financials
    Income statement
    Revenue$22.5M
    Gross profit
    Operating income
    Net income-$3.3M
    Margins
    Gross margin
    Operating margin
    Net margin-14.9%
    FCF margin
    Balance sheet
    Total assets
    Total liabilities$50.9M
    Total equity$21.0M
    Cash & equivalents$35.5M
    Long-term debt$18.8M
    Cash flow
    Operating cash flow-$5.0M
    CapEx-$415.0k
    Free cash flow
    SBC
    Highlights
    • Revenue $22.5M
    • Net margin -14.9%

    Valuation FY

    Market price
    $5,40
    Market cap
    $156.6M
    Enterprise value
    $153.1M
    P/E
    Non-GAAP P/E
    EV / Revenue
    2.8x
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$20.8M
    Net cash
    $3.5M
    Current ratio
    1.0
    Debt / equity
    -0.6
    ROA
    -2.5%
    ROE
    5.5%
    Cash conversion
    586.0%
    CapEx / revenue
    -0.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryAdvanced Medical Equipment & Technology170,9B node revenueTMO 26,1%DHR 14,4%GEHC 12,1%PHG 11,9%BSX 11,7%ISRG 5,9%A 4,1%EW 3,5%Other 10,4%
    Source: company disclosures · own-taxonomy revenue-covered setOWLT 0,1% · rank #21 of 46

    Business relationships

    Business relationships4 disclosed relationships · 1 type · extracted from filings & disclosures
    Partners4
    Amazon.Com IncAMZN.OPartner95%Source ↗
    Target CorpTGT.OPartner95%Source ↗
    Walmart IncWMT.OPartner95%Source ↗

    Supply chain

    Vendors → OWLT ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSOWLTOWLTOwlet Inc4 entitiesAmazon.Com IncDepartment StoresUSBest Buy Co IncRetailersUSTarget CorpRetailUSWalmart IncFood Retail & DistributiUS
    4 mentions in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    Peer comparison8 peers · vs OWLT · multiples and returns
    TM
    TMO
    Thermo Fisher Scientific Inc
    $574,03
    214,1B USD
    P/E
    29,4x
    vs self
    Div yield
    0,3 %
    vs self
    ROE
    12,9 %
    +7,4 vs self
    DH
    DHR
    Danaher Corp
    $197,50
    140,1B USD
    P/E
    38,2x
    vs self
    Div yield
    vs self
    ROE
    6,9 %
    +1,4 vs self
    GE
    GEHC
    GE HEALTHCARE TECHNOLOGIES INC.
    $69,72
    31,9B USD
    P/E
    13,6x
    vs self
    Div yield
    0,2 %
    vs self
    ROE
    19,5 %
    +14,0 vs self
    PH
    PHG
    PHG
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BS
    BSX
    Boston Scientific Corp
    $48,54
    72,6B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    IS
    ISRG
    INTUITIVE SURGICAL, INC.
    $376,00
    133,2B USD
    P/E
    287,7x
    vs self
    Div yield
    vs self
    ROE
    3,6 %
    -1,9 vs self
    A
    A
    Agilent Technologies Inc
    $139,80
    39,6B USD
    P/E
    29,0x
    vs self
    Div yield
    0,8 %
    vs self
    ROE
    19,3 %
    +13,8 vs self
    EW
    EW
    Edwards Lifesciences Corp
    $88,82
    51,6B USD
    P/E
    44,3x
    vs self
    Div yield
    vs self
    ROE
    10,4 %
    +4,9 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,25
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    5
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,25
    Revenueno estimateno estimate127,3M USD
    Operating incomeno estimateno estimate-7,5M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution5 analysts
    Strong buy1
    Buy4
    Hold0
    Sell0
    Strong sell0
    12-month price target$14,25 · Median $14,50
    Low $13,00High $15,00
    Operating income · consensus-7,5M USD
    EPS surprise
    +56,0 %
    reported vs consensus · beat
    Revenue surprise
    −16,9 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$13,00
    Mean$14,25
    Median$14,50
    High$15,00
    Spot$5,40
    +163.9 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-10,8 %Above median
    Net Margin-5,5 %Above median
    ROE5,5 %Above median
    Capex / Rev-0,4 %Above P75
    D/E-0,57Best in class
    Cash Conv5,86Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net disposed 14 402 979 sh9 transactions5 insiders
    • Kim John C.Director · Warrant (Right to Buy) → Common StockDisposed 131 195 @ $4,44disposition · 2025-10-10
    • Workman KurtDirector · Warrant (Right to Buy) → Common StockDisposed 131 195 @ $4,44disposition · 2025-10-10
    • Kim John C.Director · Warrant (Right to Buy) → Common StockDisposed 48 621 @ $4,09disposition · 2025-10-10
    • Trilogy Equity Partners, LLC10% owner · Warrant (Right to Buy) → Common StockDisposed 712 915conversion · 2025-10-10
    • Trilogy Equity Partners, LLC10% owner · Warrant (Right to Buy) → Common StockDisposed 444 601conversion · 2025-10-10
    • Eclipse Continuity GP I, LLCDirector, 10% owner, Director by Deputization · Series A Warrants (Right to Purchase Shares of Common Stock) → Common StockDisposed 5 300 291disposition · 2025-10-10
    • Eclipse Continuity GP I, LLCDirector, 10% owner, Director by Deputization · Series B Warrants (Right to Purchase Shares of Common Stock) → Common StockDisposed 1 166 935disposition · 2025-10-10
    • Susan LiorDirector, 10% owner · Series B Warrants (Right to Purchase Shares of Common Stock) → Class A Common StockDisposed 1 166 935disposition · 2025-10-10
    • Susan LiorDirector, 10% owner · Series A Warrants (Right to Purchase Shares of Common Stock) → Class A Common StockDisposed 5 300 291disposition · 2025-10-10

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • Owlet Inc Market data — financials · 2026-05-28
    • Owlet Inc Market data — analyst estimates · 2026-05-28
    • Owlet Inc Market data — ESG · 2026-05-28

    Ownership & reference

    Top holders

    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$6M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$14M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$1M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$1M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M

    Insider activity

    Net selling0 buys · 12 sellsnet -$827K9 insiders · last 365d
    • Workman KurtPresident & CEO · Common StockOther 850 000 · 2026-04-28
    • Crawford AmandaChief Financial Officer · Common StockOther 141 @ $5,66$798 · 2026-04-15
    • Crawford AmandaChief Financial Officer · Common StockOther 32 032 @ $4,92$158K · 2026-04-03
    • Crawford AmandaChief Financial Officer · Common StockOther 9 242 @ $5,10$47K · 2026-04-03
    • Crawford AmandaChief Financial Officer · Common StockOther 19 191 @ $5,11$98K · 2026-03-25
    • Crawford AmandaChief Financial Officer · Common StockSold 6 892 @ $11,50$79K · 2026-02-27
    • Harris JonathanFormer President & CEO · Common StockSold 12 676 @ $11,50$146K · 2026-02-26
    • Harris JonathanFormer President & CEO · Common StockOther 41 666 · 2026-02-26
    • Crawford AmandaChief Financial Officer · Common StockOther 20 833 · 2026-02-25
    • Harris JonathanFormer President & CEO · Common StockSold 3 540 @ $10,65$38K · 2026-02-17
    • Crawford AmandaChief Financial Officer · Common StockSold 183 @ $13,33$2K · 2026-01-20
    • Harris JonathanPresident and CEO · Common StockSold 2 311 @ $13,33$31K · 2026-01-20
    • Harris JonathanFormer President & CEO · Common StockSold 3 423 @ $10,49$36K · 2025-11-17
    • Kim John C.Director · Common StockOther 18 996 · 2025-10-16
    • Harris JonathanFormer President & CEO · Common StockSold 1 851 @ $8,75$16K · 2025-10-16
    • Crawford AmandaChief Financial Officer · Common StockSold 149 @ $8,75$1K · 2025-10-16
    • Durr LauraDirector · Common StockOther 18 996 · 2025-10-16
    • Gonzales MelissaDirector · Common StockOther 18 996 · 2025-10-16
    • Eclipse Continuity GP I, LLCDirector, 10% owner, Director by Deputization · Common StockOther 3 898 906 · 2025-10-10
    • Workman KurtDirector · Common StockOther 80 235 · 2025-10-10
    • Kim John C.Director · Common StockOther 107 626 · 2025-10-10
    • Trilogy Equity Partners, LLC10% owner · Common StockOther 686 469 · 2025-10-10
    • Susan LiorDirector, 10% owner · Common StockOther 3 898 906 · 2025-10-10
    • Workman KurtPresident & CEO · Common StockSold 49 056 @ $8,46$415K · 2025-10-03
    • Harris JonathanFormer President & CEO · Common StockOther 60 024 · 2025-09-30

    Short positioning

    521.6Kshares short+8.0% vs prior
    2.89days to cover
    38.3%short of daily vol
    169fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    OWLT.KCanonical
    NYSE · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.
    Relationship graph
    OWLTAMZN.OBBY.OTGT.OWMT.OAdvanced Medic
    This companySectorPartners

    Evidence & claims

    From filings & derived data
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -24.4%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 72.9%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 164.0%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 35.4%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): 43.6%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 59.1%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 3.7%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -216.5%Derived (calculated)
    • Gross margin (FY 2025-12-31): 50.6%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -43.1%Derived (calculated)
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): 36.2%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -47.1%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 34.7%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 75.2%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 680.0%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 2.64xDerived (calculated)
    • Current ratio (FY 2025-12-31): 1.85xDerived (calculated)
    • Return on assets (FY 2025-12-31): -46.3%Derived (calculated)
    • Return on equity (FY 2025-12-31): -208.4%Derived (calculated)
    • Net margin (FY 2025-12-31): -37.5%Derived (calculated)
    • Shares outstanding (annual): 26.95MSEC XBRL filing
    • Operating cash flow (annual): USD -10.79MSEC XBRL filing
    • Current assets (annual): USD 81.92MSEC XBRL filing
    • Total assets (annual): USD 85.63MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-05FILING8-K filing →
    2026-05-11FILING10-Q filing →
    2026-05-07 16:05 UTCEARNINGSQuarterly results — Q1 2026 Revenue USD 22.5M · Net USD -3.3M
    2026-05-07FILING8-K filing →
    2026-04-28 00:00 UTCINSIDER4 insider transactions — 2026-04 · net buy $110k
    2026-04-28INSIDERWorkman Kurt transacted 850.0k sh — President & CEO
    2026-04-15INSIDERCrawford Amanda transacted 141 sh — Chief Financial Officer ~$1k
    2026-04-06FILING8-K filing →
    2026-04-03INSIDERCrawford Amanda transacted 32.0k sh — Chief Financial Officer ~$158k
    2026-04-03INSIDERCrawford Amanda transacted 9.2k sh — Chief Financial Officer ~$47k
    2026-03-25 00:00 UTCINSIDER1 insider transaction — 2026-03
    2026-03-25INSIDERCrawford Amanda transacted 19.2k sh — Chief Financial Officer ~$98k
    2026-03-09FILING10-K filing →
    2026-03-05 16:05 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 26.6M · Net USD -9.2M
    2026-03-05FILING8-K filing →
    2026-02-27 00:00 UTCINSIDER5 insider transactions — 2026-02 · net sell $263k
    2026-02-27INSIDERCrawford Amanda sold 6.9k sh — Chief Financial Officer ~$79k
    2026-02-26INSIDERHarris Jonathan sold 12.7k sh — Former President & CEO ~$146k
    2026-02-26INSIDERHarris Jonathan transacted 41.7k sh — Former President & CEO
    2026-02-25INSIDERCrawford Amanda transacted 20.8k sh — Chief Financial Officer
    2026-02-17INSIDERHarris Jonathan sold 3.5k sh — Former President & CEO ~$38k
    2026-02-05FILING8-K filing →
    2026-01-20 00:00 UTCINSIDER2 insider transactions — 2026-01
    2026-01-20INSIDERCrawford Amanda sold 183 sh — Chief Financial Officer ~$2k
    2026-01-20INSIDERHarris Jonathan sold 2.3k sh — President and CEO ~$31k
    2025-12-12FILING424B3 filing →
    2025-11-17 00:00 UTCINSIDER1 insider transaction — 2025-11
    2025-11-17INSIDERHarris Jonathan sold 3.4k sh — Former President & CEO ~$36k
    2025-11-13FILING10-Q filing →
    2025-11-13FILING8-K filing →
    2025-10-23FILING8-K filing →
    2025-10-23FILING424B5 filing →
    2025-10-16 00:00 UTCINSIDER20 insider transactions — 2025-10 · net sell $433k 9 derivative
    2025-10-16INSIDERKim John C. transacted 19.0k sh — Director
    2025-10-16INSIDERHarris Jonathan sold 1.9k sh — Former President & CEO ~$16k
    2025-10-16INSIDERCrawford Amanda sold 149 sh — Chief Financial Officer ~$1k
    2025-10-16INSIDERDurr Laura transacted 19.0k sh — Director
    2025-10-16INSIDERGonzales Melissa transacted 19.0k sh — Director
    Showing the 40 most recent of 62 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage